Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials

Nature Reviews Clinical Oncology, Published online: 10 April 2024; doi:10.1038/s41571-024-00886-yThe benefit of combining antiangiogenic agents with immune-checkpoint inhibitors has been demonstrated in pivotal phase III trials across different cancer types, some with practice-changing results; however, other phase III trials have had negative results. The authors of this Perspective discuss the variable outcomes of these trials, considering factors that account for these differences and suggesting future initiatives for improving the outcomes in patients receiving these combinations.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research